Skip to Content

Chugai Pharmaceutical Co Ltd

4519: XTKS (JPN)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
JPY 7,327.00JcmgrfJpkvgthq

Chugai Earnings: Slightly Missed Expectations but Still On Track for Full-Year Target

Narrow-moat Chugai's first-quarter earnings were slightly below our expectations mostly due to lower-than-expected royalty income. However, this is still well within the usual quarterly variability, and overall we think the company remains on track to meet its full year guidance. We maintain our fair value estimate of JPY 5,200 per share. Although the market price is close to our fair value estimate, given our positive view of Chugai's pipeline, we think this stock is worth watching closely and potentially buying on dips.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of 4519 so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center